Our endocrine month in review spotlights the most popular articles from the past month. This month's top articles include the approval of tirzepatide, news from AACE & ATTD, and a pair of podcast episodes.
Recorded less than a week after approval, the latest episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives broke down what the tirzepatide approval means for clinicians and patients.
Later in the episode, hosts take a deep dive into their takeaways from the American Association of Clinical Endocrinology (AACE) 2022 annual meeting and discuss how a recent acquisition by a major company might impact care in the future.
Data from the Insulin-Only Bionic Pancreas Pivotal Trial was presented at the 15th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD).
Results of the study suggest use of the iLet Bionic Pancreas, produced by Beta Bionics Inc., was associated with significant reductions in HbA1c and improved time in range compared with standard care in patients with type 1 diabetes.
A systematic review and meta-analysis presented at AACE 2022 examined the risk of Parkinson disease among patients with hypothyroidism and hyperthyroidism.
Results of the study indicated patients with thyroid dysfunction were at increased risk of Parkinson disease, with increases in likelihood of 56% and 57% for hypothyroidism and hyperthyroidism, respectively.
Our first episode in May, this episode of Diabetes Dialogue was dedicated to discussions surrounding ATTD 2022.
Highlights of the episode include reactions to the SURMOUNT-1 topline results and a deep dive into our hosts’ favorite sessions from the conference, including the latest updates in the world of diabetes smartphone apps, smart insulin pens, and CGM systems.
The latest update from the Diabetes Prevention Program Outcomes Study (DPPOS) suggests neither metformin nor lifestyle interventions were associated with a reduction in risk of major adverse cardiovascular events.
In adjusted analyses with a time-weighted mean follow-up of 21 years, no reduction in risk was observed for MACE based on use of metformin (HR, 1.03 [95% CI, 0.78-1.37]; P=.81) or lifestyle interventions (HR, 1.14 [95% CI, 0.87-1.50]; P=.34).